mipasetamab uzoptirine (ADCT-601) - Overland ADCT BioPharma
NaPi2b-PL2202 - ADC Therapeutics
ADCT-701 - ADC Therapeutics
Zynlonta (loncastuximab tesirine-lpyl) - Overland ADCT BioPharma
https://www.globenewswire.com/news-release/2024/03/05/2840990/0/en/ADC-Therapeutics-Announces-Abstracts-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html
 
Mar 5, 2024
 
Prev Next